Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents?

Peter Dreger, Johannes Schetelig, Niels Andersen, Paolo Corradini, Michel Van Gelder, John Gribben, Eva Kimby, Mauricette Michallet, Carol Moreno, Stephan Stilgenbauer, Emili Montserrat

Research output: Contribution to journalArticlepeer-review

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [

Original languageEnglish
Pages (from-to)3841-3849
Number of pages9
JournalBlood
Volume124
Issue number26
DOIs
Publication statusPublished - Dec 18 2014

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents?'. Together they form a unique fingerprint.

Cite this